Published in N Engl J Med on August 07, 2008
Cardiorenal Risk Stratification Pilot Study (CRiSPS) | NCT03628443
FGF23 induces left ventricular hypertrophy. J Clin Invest (2011) 7.22
The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov (2009) 6.23
Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA (2011) 5.86
The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: the Heart and Soul Study. Ann Intern Med (2010) 4.89
Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation (2009) 4.87
Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int (2011) 4.74
FGF-23 associates with death, cardiovascular events, and initiation of chronic dialysis. J Am Soc Nephrol (2011) 3.52
Phosphorus binders and survival on hemodialysis. J Am Soc Nephrol (2008) 3.26
Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy? Clin J Am Soc Nephrol (2009) 2.81
FGF23 is independently associated with vascular calcification but not bone mineral density in patients at various CKD stages. Osteoporos Int (2011) 2.71
Diuretics, calciuria and secondary hyperparathyroidism in the Chronic Renal Insufficiency Cohort. Nephrol Dial Transplant (2011) 2.60
Elevated fibroblast growth factor 23 is a risk factor for kidney transplant loss and mortality. J Am Soc Nephrol (2011) 2.59
Targeted deletion of Klotho in kidney distal tubule disrupts mineral metabolism. J Am Soc Nephrol (2012) 2.48
FGF23 neutralization improves chronic kidney disease-associated hyperparathyroidism yet increases mortality. J Clin Invest (2012) 2.41
Racial differences in the relationship between vitamin D, bone mineral density, and parathyroid hormone in the National Health and Nutrition Examination Survey. Osteoporos Int (2010) 2.35
The FGF23-Klotho axis: endocrine regulation of phosphate homeostasis. Nat Rev Endocrinol (2009) 2.26
Pilot study of dietary phosphorus restriction and phosphorus binders to target fibroblast growth factor 23 in patients with chronic kidney disease. Nephrol Dial Transplant (2010) 2.23
Fibroblast growth factor-23 and death, heart failure, and cardiovascular events in community-living individuals: CHS (Cardiovascular Health Study). J Am Coll Cardiol (2012) 2.22
Endocrine functions of bone in mineral metabolism regulation. J Clin Invest (2008) 2.19
Circulating fibroblast growth factor 23 in patients with end-stage renal disease treated by peritoneal dialysis is intact and biologically active. J Clin Endocrinol Metab (2009) 2.12
Fibroblast growth factor 23 and risk of incident stroke in community-living adults. Stroke (2015) 2.06
Regulation and function of the FGF23/klotho endocrine pathways. Physiol Rev (2012) 1.97
Phosphate binder use and mortality among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS): evaluation of possible confounding by nutritional status. Am J Kidney Dis (2012) 1.91
Early chronic kidney disease-mineral bone disorder stimulates vascular calcification. Kidney Int (2013) 1.90
Outcomes associated with phosphorus binders in men with non-dialysis-dependent CKD. Am J Kidney Dis (2010) 1.82
Update on fibroblast growth factor 23 in chronic kidney disease. Kidney Int (2012) 1.82
Fibroblast growth factor-23 and cardiovascular events in CKD. J Am Soc Nephrol (2013) 1.78
Phosphate feeding induces arterial medial calcification in uremic mice: role of serum phosphorus, fibroblast growth factor-23, and osteopontin. Kidney Int (2009) 1.77
Vitamin D deficiency is associated with sudden cardiac death, combined cardiovascular events, and mortality in haemodialysis patients. Eur Heart J (2010) 1.72
Fibroblast growth factor 23 is not associated with and does not induce arterial calcification. Kidney Int (2013) 1.66
Primary osteoblast-like cells from patients with end-stage kidney disease reflect gene expression, proliferation, and mineralization characteristics ex vivo. Kidney Int (2014) 1.65
Fibroblast growth factor 23 and fetuin A are independent predictors for the coronary artery disease extent in mild chronic kidney disease. Clin J Am Soc Nephrol (2010) 1.65
FGF-23: More than a regulator of renal phosphate handling? J Bone Miner Res (2010) 1.63
Emerging risk factors and markers of chronic kidney disease progression. Nat Rev Nephrol (2009) 1.58
FGF23 signaling impairs neutrophil recruitment and host defense during CKD. J Clin Invest (2016) 1.57
Effects of dietary phosphate and calcium intake on fibroblast growth factor-23. Clin J Am Soc Nephrol (2010) 1.53
Familial tumoral calcinosis: from characterization of a rare phenotype to the pathogenesis of ectopic calcification. J Invest Dermatol (2009) 1.51
Fibroblast growth factor-23 and early decrements in kidney function: the Heart and Soul Study. Nephrol Dial Transplant (2009) 1.51
Plasma fibroblast growth factor 23, parathyroid hormone, phosphorus, and risk of coronary heart disease. Am Heart J (2011) 1.49
Stat3 activation links a C/EBPδ to myostatin pathway to stimulate loss of muscle mass. Cell Metab (2013) 1.49
Fibroblast growth factor 23 and Inflammation in CKD. Clin J Am Soc Nephrol (2012) 1.48
Associations of dietary phosphorus intake, urinary phosphate excretion, and fibroblast growth factor 23 with vascular stiffness in chronic kidney disease. J Ren Nutr (2012) 1.46
Race, Mineral Homeostasis and Mortality in Patients with End-Stage Renal Disease on Dialysis. Am J Nephrol (2015) 1.46
Phosphate control in end-stage renal disease: barriers and opportunities. Nephrol Dial Transplant (2013) 1.46
Paricalcitol versus cinacalcet plus low-dose vitamin D for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: study design and baseline characteristics of the IMPACT SHPT study. Nephrol Dial Transplant (2011) 1.46
Low socioeconomic status associates with higher serum phosphate irrespective of race. J Am Soc Nephrol (2010) 1.46
Association of dietary phosphorus intake and phosphorus to protein ratio with mortality in hemodialysis patients. Clin J Am Soc Nephrol (2010) 1.45
Association of fibroblast growth factor-23 with arterial stiffness in the Multi-Ethnic Study of Atherosclerosis. Nephrol Dial Transplant (2014) 1.44
FGF23 fails to inhibit uremic parathyroid glands. J Am Soc Nephrol (2010) 1.42
Cross talk between the renin-angiotensin-aldosterone system and vitamin D-FGF-23-klotho in chronic kidney disease. J Am Soc Nephrol (2011) 1.42
Plasma FGF23 and Calcified Atherosclerotic Plaque in African Americans with Type 2 Diabetes Mellitus. Am J Nephrol (2015) 1.42
Plasma FGF23 levels increase rapidly after acute kidney injury. Kidney Int (2013) 1.42
Role of FGF23 in vitamin D and phosphate metabolism: implications in chronic kidney disease. Exp Cell Res (2012) 1.41
Mineral metabolites and CKD progression in African Americans. J Am Soc Nephrol (2012) 1.41
Skeletal secretion of FGF-23 regulates phosphate and vitamin D metabolism. Nat Rev Endocrinol (2012) 1.37
Fibroblast growth factor 23, cardiovascular disease risk factors, and phosphorus intake in the health professionals follow-up study. Clin J Am Soc Nephrol (2011) 1.36
Prescribed dietary phosphate restriction and survival among hemodialysis patients. Clin J Am Soc Nephrol (2010) 1.31
Effects of cinacalcet and concurrent low-dose vitamin D on FGF23 levels in ESRD. Clin J Am Soc Nephrol (2009) 1.30
Longitudinal evaluation of FGF23 changes and mineral metabolism abnormalities in a mouse model of chronic kidney disease. J Bone Miner Res (2012) 1.28
Activation of Cardiac Fibroblast Growth Factor Receptor 4 Causes Left Ventricular Hypertrophy. Cell Metab (2015) 1.27
The role of phosphorus in the development and progression of vascular calcification. Am J Kidney Dis (2011) 1.26
Early skeletal and biochemical alterations in pediatric chronic kidney disease. Clin J Am Soc Nephrol (2011) 1.25
Carbamylation of serum albumin as a risk factor for mortality in patients with kidney failure. Sci Transl Med (2013) 1.25
FGF-23 as a predictor of renal outcome in diabetic nephropathy. Clin J Am Soc Nephrol (2010) 1.22
The new kidney disease: improving global outcomes (KDIGO) guidelines - expert clinical focus on bone and vascular calcification. Clin Nephrol (2010) 1.21
Fibroblast growth factor 23: state of the field and future directions. Trends Endocrinol Metab (2012) 1.21
Fibroblast growth factor-23 in early chronic kidney disease: additional support in favor of a phosphate-centric paradigm for the pathogenesis of secondary hyperparathyroidism. Clin J Am Soc Nephrol (2010) 1.21
CKD-mineral and bone disorder: core curriculum 2011. Am J Kidney Dis (2011) 1.20
Serum phosphate and mortality in patients with chronic kidney disease. Clin J Am Soc Nephrol (2010) 1.20
A comparative transcriptome analysis identifying FGF23 regulated genes in the kidney of a mouse CKD model. PLoS One (2012) 1.20
Phosphate and FGF-23. Kidney Int Suppl (2011) 1.19
The extracellular matrix in the kidney: a source of novel non-invasive biomarkers of kidney fibrosis? Fibrogenesis Tissue Repair (2014) 1.19
Elevated FGF 23 and phosphorus are associated with coronary calcification in hemodialysis patients. Pediatr Nephrol (2011) 1.18
Impact of poverty on serum phosphate concentrations in the Third National Health and Nutrition Examination Survey. J Ren Nutr (2010) 1.18
Fibroblast growth factor 23 inhibits extrarenal synthesis of 1,25-dihydroxyvitamin D in human monocytes. J Bone Miner Res (2013) 1.17
Plasma gelsolin and circulating actin correlate with hemodialysis mortality. J Am Soc Nephrol (2009) 1.16
Determinants of left ventricular mass in patients on hemodialysis: Frequent Hemodialysis Network (FHN) Trials. Circ Cardiovasc Imaging (2012) 1.16
Overview of the FGF23-Klotho axis. Pediatr Nephrol (2009) 1.15
Role of Klotho in aging, phosphate metabolism, and CKD. Am J Kidney Dis (2011) 1.15
A plasma long-chain acylcarnitine predicts cardiovascular mortality in incident dialysis patients. J Am Heart Assoc (2013) 1.15
Regulation of phosphate transport by fibroblast growth factor 23 (FGF23): implications for disorders of phosphate metabolism. Pediatr Nephrol (2009) 1.14
FGF-23 and secondary hyperparathyroidism in chronic kidney disease. Nat Rev Nephrol (2013) 1.14
Reduced renal α-Klotho expression in CKD patients and its effect on renal phosphate handling and vitamin D metabolism. PLoS One (2014) 1.13
Fibroblast growth factor 23 in patients undergoing peritoneal dialysis. Clin J Am Soc Nephrol (2011) 1.13
Miscellaneous non-inflammatory musculoskeletal conditions. Hyperphosphatemic familial tumoral calcinosis (FGF23, GALNT3 and αKlotho). Best Pract Res Clin Rheumatol (2011) 1.13
Dietary phosphate restriction suppresses phosphaturia but does not prevent FGF23 elevation in a mouse model of chronic kidney disease. Kidney Int (2013) 1.13
Does FGF23 toxicity influence the outcome of chronic kidney disease? Nephrol Dial Transplant (2008) 1.12
Racial differences in postprandial mineral ion handling in health and in chronic kidney disease. Nephrol Dial Transplant (2010) 1.11
Serum FGF23 and risk of cardiovascular events in relation to mineral metabolism and cardiovascular pathology. Clin J Am Soc Nephrol (2013) 1.10
Familial tumoral calcinosis and the role of O-glycosylation in the maintenance of phosphate homeostasis. Biochim Biophys Acta (2008) 1.10
FGF23, albuminuria, and disease progression in patients with chronic IgA nephropathy. Clin J Am Soc Nephrol (2012) 1.09
Calcium regulates FGF-23 expression in bone. Endocrinology (2013) 1.09
Arterial klotho expression and FGF23 effects on vascular calcification and function. PLoS One (2013) 1.09
Parathyroid-specific deletion of Klotho unravels a novel calcineurin-dependent FGF23 signaling pathway that regulates PTH secretion. PLoS Genet (2013) 1.09
Fibroblast growth factor-23 is associated with C-reactive protein, serum phosphate and bone mineral density in chronic kidney disease. Osteoporos Int (2009) 1.08
Fibroblast growth factor-23 and incident coronary heart disease, heart failure, and cardiovascular mortality: the Atherosclerosis Risk in Communities study. J Am Heart Assoc (2014) 1.07
Phosphate and cardiovascular disease. Adv Chronic Kidney Dis (2011) 1.06
FGF23: instability may affect accuracy and interpretation. Osteoporos Int (2012) 1.06
Disordered FGF23 and mineral metabolism in children with CKD. Clin J Am Soc Nephrol (2013) 1.05
Association of serum alkaline phosphatase and bone mineral density in maintenance hemodialysis patients. Hemodial Int (2010) 1.05
Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med (2004) 49.19
Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol (2004) 11.23
Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med (2003) 8.87
Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet (2000) 7.41
Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest (2004) 7.00
Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci U S A (2001) 6.70
Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int (2006) 6.61
Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol (2004) 6.59
Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med (2003) 6.41
Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int (2007) 6.35
Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol (2005) 5.76
Relation between serum phosphate level and cardiovascular event rate in people with coronary disease. Circulation (2005) 5.29
The parathyroid is a target organ for FGF23 in rats. J Clin Invest (2007) 4.47
Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol (2005) 4.44
Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int (2003) 3.75
Disparities in incidence of diabetic end-stage renal disease according to race and type of diabetes. N Engl J Med (1989) 3.67
Regulation of C-terminal and intact FGF-23 by dietary phosphate in men and women. J Bone Miner Res (2006) 3.66
The autosomal dominant hypophosphatemic rickets (ADHR) gene is a secreted polypeptide overexpressed by tumors that cause phosphate wasting. J Clin Endocrinol Metab (2001) 3.55
An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia. Hum Mol Genet (2004) 3.42
Changes in serum calcium, phosphate, and PTH and the risk of death in incident dialysis patients: a longitudinal study. Kidney Int (2006) 3.36
Dietary phosphorus regulates serum fibroblast growth factor-23 concentrations in healthy men. J Clin Endocrinol Metab (2006) 3.08
Impact of activated vitamin D and race on survival among hemodialysis patients. J Am Soc Nephrol (2008) 2.96
Evidence for alteration of the vitamin D-endocrine system in blacks. J Clin Invest (1985) 2.72
Circulating FGF-23 is regulated by 1alpha,25-dihydroxyvitamin D3 and phosphorus in vivo. J Biol Chem (2004) 2.72
Revisiting survival differences by race and ethnicity among hemodialysis patients: the Dialysis Outcomes and Practice Patterns Study. J Am Soc Nephrol (2006) 2.65
Effect of manipulating serum phosphorus with phosphate binder on circulating PTH and FGF23 in renal failure rats. Kidney Int (2006) 2.57
Analysis of the biochemical mechanisms for the endocrine actions of fibroblast growth factor-23. Endocrinology (2005) 2.46
Role of hyperphosphatemia and 1,25-dihydroxyvitamin D in vascular calcification and mortality in fibroblastic growth factor 23 null mice. J Am Soc Nephrol (2007) 2.16
Pathogenesis of vascular calcification in chronic kidney disease. Kidney Int (2005) 2.15
Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency. Am J Kidney Dis (2004) 1.93
Tumors associated with oncogenic osteomalacia express genes important in bone and mineral metabolism. J Bone Miner Res (2002) 1.84
Sevelamer hydrochloride and calcium bicarbonate reduce serum fibroblast growth factor 23 levels in dialysis patients. Ther Apher Dial (2005) 1.78
Genetic ablation of vitamin D activation pathway reverses biochemical and skeletal anomalies in Fgf-23-null animals. Am J Pathol (2006) 1.75
Survival advantage for adult Hispanic hemodialysis patients? Findings from the end-stage renal disease clinical performance measures project. J Am Soc Nephrol (2003) 1.58
NHANES III: influence of race on GFR thresholds and detection of metabolic abnormalities. J Am Soc Nephrol (2007) 1.50
Prevalence and severity of disordered mineral metabolism in Blacks with chronic kidney disease. Kidney Int (2008) 1.44
Skeletal abnormalities in chronic renal insufficiency before and during maintenance hemodialysis. Kidney Int (1973) 1.18
Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med (2004) 14.00
Vitamin D deficiency and risk of cardiovascular disease. Circulation (2008) 13.39
Trends in college binge drinking during a period of increased prevention efforts. Findings from 4 Harvard School of Public Health College Alcohol Study surveys: 1993-2001. J Am Coll Health (2002) 12.86
Vitamin D-binding protein and vitamin D status of black Americans and white Americans. N Engl J Med (2013) 9.87
Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab (2007) 9.77
Common genetic determinants of vitamin D insufficiency: a genome-wide association study. Lancet (2010) 8.89
Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med (2003) 8.87
Gonadal steroids and body composition, strength, and sexual function in men. N Engl J Med (2013) 8.47
Kidney Injury Molecule-1 (KIM-1): a novel biomarker for human renal proximal tubule injury. Kidney Int (2002) 8.03
FGF23 induces left ventricular hypertrophy. J Clin Invest (2011) 7.22
Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med (2006) 7.06
Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med (2003) 6.41
Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA (2011) 5.86
Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol (2005) 5.76
Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial. Lancet (2013) 5.57
The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med (2003) 5.45
Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. JAMA (2012) 5.27
Prevalence of cardiovascular risk factors and the serum levels of 25-hydroxyvitamin D in the United States: data from the Third National Health and Nutrition Examination Survey. Arch Intern Med (2007) 5.26
Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation (2009) 4.87
Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int (2011) 4.74
Coronary CT angiography versus standard evaluation in acute chest pain. N Engl J Med (2012) 4.72
Coronary computed tomography angiography for early triage of patients with acute chest pain: the ROMICAT (Rule Out Myocardial Infarction using Computer Assisted Tomography) trial. J Am Coll Cardiol (2009) 4.54
DMP1 mutations in autosomal recessive hypophosphatemia implicate a bone matrix protein in the regulation of phosphate homeostasis. Nat Genet (2006) 4.49
Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol (2005) 4.44
Transgenic mice expressing fibroblast growth factor 23 under the control of the alpha1(I) collagen promoter exhibit growth retardation, osteomalacia, and disturbed phosphate homeostasis. Endocrinology (2004) 3.89
Metabolic profiling of the human response to a glucose challenge reveals distinct axes of insulin sensitivity. Mol Syst Biol (2008) 3.82
Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int (2003) 3.75
Regulation of C-terminal and intact FGF-23 by dietary phosphate in men and women. J Bone Miner Res (2006) 3.66
Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. J Clin Oncol (2007) 3.65
"Ghost" publications among applicants to a general surgery residency program. J Am Coll Surg (2008) 3.64
Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large U.S. healthcare system. J Clin Endocrinol Metab (2008) 3.64
In vivo diagnosis of plaque erosion and calcified nodule in patients with acute coronary syndrome by intravascular optical coherence tomography. J Am Coll Cardiol (2013) 3.43
A blueprint for randomized trials targeting phosphorus metabolism in chronic kidney disease. Kidney Int (2009) 3.41
Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation. J Am Soc Nephrol (2009) 3.40
Cord-blood 25-hydroxyvitamin D levels and risk of respiratory infection, wheezing, and asthma. Pediatrics (2010) 3.39
Phosphorus binders and survival on hemodialysis. J Am Soc Nephrol (2008) 3.26
Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice. Matrix Biol (2004) 3.23
Efficacy of an acellular pertussis vaccine among adolescents and adults. N Engl J Med (2005) 3.21
Genetic variants and associations of 25-hydroxyvitamin D concentrations with major clinical outcomes. JAMA (2012) 3.10
Calciphylaxis from nonuremic causes: a systematic review. Clin J Am Soc Nephrol (2008) 3.00
Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab (2006) 2.98
Impact of activated vitamin D and race on survival among hemodialysis patients. J Am Soc Nephrol (2008) 2.96
Effects of phosphate binders in moderate CKD. J Am Soc Nephrol (2012) 2.92
High-sensitivity troponin T concentrations in acute chest pain patients evaluated with cardiac computed tomography. Circulation (2010) 2.91
Scientific writing of novice researchers: what difficulties and encouragements do they encounter? Acad Med (2009) 2.86
Sequential changes in antiangiogenic factors in early pregnancy and risk of developing preeclampsia. Hypertension (2007) 2.77
Neuropsychological measures in normal individuals that predict subsequent cognitive decline. Arch Neurol (2007) 2.77
Urinary placental growth factor and risk of preeclampsia. JAMA (2005) 2.76
Adiposity, cardiometabolic risk, and vitamin D status: the Framingham Heart Study. Diabetes (2009) 2.70
The impact of race as a risk factor for symptom severity and age at diagnosis of uterine leiomyomata among affected sisters. Am J Obstet Gynecol (2008) 2.60
Diuretics, calciuria and secondary hyperparathyroidism in the Chronic Renal Insufficiency Cohort. Nephrol Dial Transplant (2011) 2.60
Regulation of phosphate homeostasis by PTH, vitamin D, and FGF23. Annu Rev Med (2010) 2.55
Vitamin D-binding protein modifies the vitamin D-bone mineral density relationship. J Bone Miner Res (2011) 2.55
Reversal of idiopathic hypogonadotropic hypogonadism. N Engl J Med (2007) 2.54
Relationship between testosterone levels, insulin sensitivity, and mitochondrial function in men. Diabetes Care (2005) 2.52
Vitamin D reduces left atrial volume in patients with left ventricular hypertrophy and chronic kidney disease. Am Heart J (2012) 2.42
Nonculprit plaques in patients with acute coronary syndromes have more vulnerable features compared with those with non-acute coronary syndromes: a 3-vessel optical coherence tomography study. Circ Cardiovasc Imaging (2012) 2.34
Low plasma level of cathelicidin antimicrobial peptide (hCAP18) predicts increased infectious disease mortality in patients undergoing hemodialysis. Clin Infect Dis (2009) 2.34
Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism. Kidney Int (2010) 2.31
Hypoparathyroidism in the adult: epidemiology, diagnosis, pathophysiology, target-organ involvement, treatment, and challenges for future research. J Bone Miner Res (2011) 2.30
Vitamin D deficiency and cardiovascular events in patients with coronary heart disease: data from the Heart and Soul Study. Am J Epidemiol (2014) 2.30
Activated vitamin D attenuates left ventricular abnormalities induced by dietary sodium in Dahl salt-sensitive animals. Proc Natl Acad Sci U S A (2007) 2.25
Pilot study of dietary phosphorus restriction and phosphorus binders to target fibroblast growth factor 23 in patients with chronic kidney disease. Nephrol Dial Transplant (2010) 2.23
Clinical characterization and outcomes of preeclampsia with normal angiogenic profile. Hypertens Pregnancy (2013) 2.22
A mutant PTH/PTHrP type I receptor in enchondromatosis. Nat Genet (2002) 2.19
Early outcomes among those initiating chronic dialysis in the United States. Clin J Am Soc Nephrol (2011) 2.17
Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer: differences from the classic metabolic syndrome. Cancer (2008) 2.16
Circulating fibroblast growth factor 23 in patients with end-stage renal disease treated by peritoneal dialysis is intact and biologically active. J Clin Endocrinol Metab (2009) 2.12
First trimester placental growth factor and soluble fms-like tyrosine kinase 1 and risk for preeclampsia. J Clin Endocrinol Metab (2004) 2.11
Ollier disease. Orphanet J Rare Dis (2006) 2.11
Association of serum bicarbonate with risk of renal and cardiovascular outcomes in CKD: a report from the Chronic Renal Insufficiency Cohort (CRIC) study. Am J Kidney Dis (2013) 2.09
Validation of a scoring system to predict recurrence of resected solitary fibrous tumors of the pleura. Chest (2015) 2.04